CIK: 0001595855
Total reported value
$759.2M
Reporting period: 2026-03-31 · Number of holdings: 54
Opaleye Management Inc. disclosed 54 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $759.2M and a quarterly turnover rate of 47.8%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "O"
Opaleye Management Inc.'s disclosed holdings carry a Herfindahl concentration index of 0.057 — mathematically equivalent to about 18 equally-sized positions, well below its 54 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 1.45), with a handful of outsized bets alongside many smaller positions.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 4% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim HROW
-27.5% -$91.5M
Add ETON
0.0% $22.2M
Add M8694L137
+10.2% $20.5M
Add URGN
+432.7% $19.4M
Add MGTX
+443.2% $15.3M
Add CATX
+294.7% $14.5M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | HROW | Harrow INC | Stock-Other | 13.15% | -12.10% | -27.47% | |
| 2 | LQDA | Liquidia CORP | Stock-Other | 11.70% | +0.49% | +4.52% | |
| 3 | ETON | Eton Pharmaceuticals INC | Stock-Other | 9.30% | +2.92% | — | |
| 4 | ✓ | Stock-Other | 5.22% | +2.70% | +10.20% | ||
| 5 | RYTM | Rhythm Pharmaceuticals INC | Stock-Other | 4.65% | — | -62.73% | |
| 6 | APGE | Apogee Therapeutics INC | Stock-Other | 4.32% | +0.45% | +0.45% | |
| 7 | IRON | Disc Medicine INC | Stock-Other | 3.55% | +1.45% | +110.50% | |
| 8 | URGN | UroGen Pharma Ltd. | Stock-Other | 3.39% | +2.56% | +432.74% | |
| 9 | ✓ | Crescent Biopharma INC. | Stock-Other | 3.18% | +1.34% | +11.40% | |
| 10 | STOK | Stoke Therapeutics INC | Stock-Other | 3.00% | +0.09% | +0.72% | |
| 11 | CATX | Perspective Therapeutics INC | Stock-Other | 2.57% | +1.91% | +294.68% | |
| 12 | RZLT | Rezolute INC | Stock-Other | 2.53% | +0.57% | +0.20% | |
| 13 | MGTX | MeiraGTx Holdings plc | Stock-Other | 2.42% | +2.01% | +443.25% | |
| 14 | TGTX | Tg Therapeutics INC | Stock-Healthcare | 2.34% | +0.24% | — | |
| 15 | SNWV | Sanuwave Health INC | Stock-Other | 2.23% | -1.63% | — | |
| 16 | EWTX | Edgewise Therapeutics INC | Stock-Other | 2.07% | +0.43% | — | |
| 17 | ACOG | Alpha Cognition INC | Stock-Other | 1.85% | +0.07% | +23.72% | |
| 18 | ANNX | Annexon INC | Stock-Other | 1.70% | — | -10.32% | |
| 19 | ALMS | Alumis INC | Stock-Other | 1.60% | +0.91% | +2.80% | |
| 20 | CDXS | Codexis INC | Stock-Other | 1.46% | — | -0.07% | |
| 21 | PTGX | Protagonist Therapeutics INC | Stock-Other | 1.39% | +0.18% | -4.76% | |
| 22 | RVMD | Revolution Medicines INC | Stock-Healthcare | 1.28% | +0.23% | — | |
| 23 | XOMA | Xoma Royalty Corporation | Stock-Other | 1.24% | +0.21% | +2.53% | |
| 24 | QTTB | Q32 Bio INC | Stock-Other | 1.06% | +0.97% | +488.77% | |
| 25 | MBX | Mbx Biosciences INC | Stock-Other | 1.02% | — | — | |
| 26 | RLMD | Relmada Therapeutics INC | Stock-Other | 0.86% | +0.26% | — | |
| 27 | CGON | Cg Oncology INC | Stock-Other | 0.85% | -1.40% | -76.88% | |
| 28 | JBIO | Jade Biosciences INC | Stock-Other | 0.79% | -0.08% | — | |
| 29 | OCUL | Ocular Therapeutix INC | Stock-Other | 0.67% | -1.88% | -62.38% | |
| 30 | AH30 | Assertio Holdings INC | Stock-Other | 0.67% | +0.67% | NEW | |
| 31 | EDIT | Editas Medicine INC | Stock-Other | 0.63% | +0.63% | NEW | |
| 32 | STRO | Sutro Biopharma INC | Stock-Other | 0.63% | +0.34% | — | |
| 33 | DERM | Journey Medical CORP | Stock-Other | 0.59% | -0.40% | -1.54% | |
| 34 | VYGR | Voyager Therapeutics INC | Stock-Other | 0.58% | — | -3.92% | |
| 35 | TRVI | Trevi Therapeutics INC | Stock-Other | 0.54% | — | — | |
| 36 | TECX | Tectonic Therapeutic INC | Stock-Other | 0.50% | -0.09% | -42.72% | |
| 37 | CABA | Cabaletta Bio INC | Stock-Other | 0.49% | +0.23% | +53.33% | |
| 38 | BDSX | Biodesix INC | Stock-Other | 0.45% | +0.45% | NEW | |
| 39 | RCKT | Rocket Pharmaceuticals INC | Stock-Other | 0.45% | — | — | |
| 40 | ZNTL | Zentalis Pharmaceuticals INC | Stock-Other | 0.44% | +0.19% | +0.84% | |
| 41 | NTLA | Intellia Therapeutics INC | Stock-Other | 0.41% | +0.41% | NEW | |
| 42 | FBIO | Fortress Biotech INC | Stock-Other | 0.38% | -0.15% | -4.40% | |
| 43 | IRD | Opus Genetics INC | Stock-Other | 0.30% | — | — | |
| 44 | RIGL | Rigel Pharmaceuticals INC | Stock-Other | 0.25% | -0.15% | — | |
| 45 | AVIR | Atea Pharmaceuticals INC | Stock-Other | 0.23% | +0.15% | +79.41% | |
| 46 | LYEL | Lyell Immunopharma INC | Stock-Other | 0.21% | +0.21% | NEW | |
| 47 | ENTA | Enanta Pharmaceuticals INC | Stock-Other | 0.21% | — | +66.67% | |
| 48 | NXTC | Nextcure INC | Stock-Other | 0.20% | +0.20% | NEW | |
| 49 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.14% | +0.14% | NEW | |
| 50 | ✓ | Perspective Therapeutics INC | Stock-Other | 0.11% | +0.11% | NEW |
Performance for Q3 2026
+45.9%
Performance Last 4 Quarters
+72.7%
Based on 61% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 54 | $759.2M | 48 | |
| 2025-12-31 | 54 | $757.9M | 45 | |
| 2025-09-30 | 43 | $707.3M | 67 | |
| 2025-06-30 | 41 | $494.1M | 0 | |
| 2025-03-31 | 45 | $449.2M | 100 | |
| 2024-12-31 | 39 | $571.4M | 0 | |
| 2024-09-30 | 44 | $599.6M | 0 | |
| 2024-06-30 | 51 | $437.7M | 0 | |
| 2024-03-31 | 52 | $458.9M | 0 | |
| 2023-12-31 | 47 | $376.1M | 0 | |
| 2023-09-30 | 41 | $307.4M | 0 | |
| 2023-06-30 | 47 | $418.1M | 0 | |
| 2023-03-31 | 41 | $333.9M | 0 | |
| 2022-12-31 | 40 | $287.6M | 0 | |
| 2022-09-30 | 42 | $242.1M | 0 | |
| 2022-06-30 | 47 | $221.9M | 0 | |
| 2022-03-31 | 45 | $322.0M | 0 | |
| 2021-12-31 | 39 | $471.5M | 0 | |
| 2021-09-30 | 48 | $535.4M | 0 | |
| 2021-06-30 | 48 | $602.1M | 37 | |
| 2021-03-31 | 58 | $680.8M | 64 | |
| 2020-12-31 | 59 | $765.6M | 60 | |
| 2020-09-30 | 55 | $511.3M | 53 | |
| 2020-06-30 | 48 | $495.2M | 92 | |
| 2020-03-31 | 44 | $377.4M | 82 | |
| 2019-12-31 | 47 | $509.7M | 74 | |
| 2019-09-30 | 49 | $276.5M | 64 | |
| 2019-06-30 | 43 | $328.1M | 62 | |
| 2019-03-31 | 53 | $361.1M | 81 | |
| 2018-12-31 | 47 | $268.0M | 66 | |
| 2018-09-30 | 47 | $393.0M | 37 | |
| 2018-06-30 | 36 | $386.4M | 66 | |
| 2018-03-31 | 38 | $349.7M | 48 | |
| 2017-12-31 | 35 | $312.3M | 56 | |
| 2017-09-30 | 34 | $282.8M | 46 | |
| 2017-06-30 | 41 | $239.4M | 50 | |
| 2017-03-31 | 44 | $200.9M | 63 | |
| 2016-12-31 | 40 | $169.7M | 60 | |
| 2016-09-30 | 44 | $191.1M | 100 | |
| 2016-06-30 | 49 | $149.7M | 84 | 1H03579262957M3023111 |
| 2016-03-31 | 52 | $160.4M | 65 | |
| 2015-12-31 | 53 | $239.2M | 52 | |
| 2015-09-30 | 49 | $203.2M | 55 | |
| 2015-06-30 | 46 | $251.3M | 42 | |
| 2015-03-31 | 37 | $215.4M | 66 | |
| 2014-12-31 | 36 | $197.9M | 65 | |
| 2014-09-30 | 30 | $128.3M | 48 | |
| 2014-06-30 | 27 | $116.0M | 65 | |
| 2014-03-31 | 30 | $135.4M | 94 | |
| 2013-12-31 | 23 | $127.4M | 0 |
Opaleye Management Inc.'s most significant position changes for 2026-03-31: Sold out: Alkermes plc (ALKS); Sold out: Gossamer Bio INC (GOSS); Sold out: Karyopharm Therapeutics INC (KPTI); New buy: Assertio Holdings INC (AH30); New buy: Editas Medicine INC (EDIT).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ETON | Eton Pharmaceuticals INC | +2.9% | — | Unchanged |
| 2 | ✓ | +2.7% | +10.20% | Add | |
| 3 | URGN | UroGen Pharma Ltd. | +2.6% | +432.74% | Add |
| 4 | MGTX | MeiraGTx Holdings plc | +2% | +443.25% | Add |
| 5 | CATX | Perspective Therapeutics INC | +1.9% | +294.68% | Add |
| 6 | IRON | Disc Medicine INC | +1.5% | +110.50% | Add |
| 7 | ✓ | Crescent Biopharma INC. | +1.3% | +11.40% | Add |
| 8 | QTTB | Q32 Bio INC | +1% | +488.77% | Add |
| 9 | ALMS | Alumis INC | +0.9% | +2.80% | Add |
| 10 | RZLT | Rezolute INC | +0.6% | +0.20% | Add |
| 11 | LQDA | Liquidia CORP | +0.5% | +4.52% | Add |
| 12 | APGE | Apogee Therapeutics INC | +0.5% | +0.45% | Add |
| 13 | EWTX | Edgewise Therapeutics INC | +0.4% | — | Unchanged |
| 14 | STRO | Sutro Biopharma INC | +0.3% | — | Unchanged |
| 15 | RLMD | Relmada Therapeutics INC | +0.3% | — | Unchanged |
| 16 | TGTX | Tg Therapeutics INC | +0.2% | — | Unchanged |
| 17 | RVMD | Revolution Medicines INC | +0.2% | — | Unchanged |
| 18 | CABA | Cabaletta Bio INC | +0.2% | +53.33% | Add |
| 19 | XOMA | Xoma Royalty Corporation | +0.2% | +2.53% | Add |
| 20 | ZNTL | Zentalis Pharmaceuticals INC | +0.2% | +0.84% | Add |
| 21 | PTGX | Protagonist Therapeutics INC | +0.2% | -4.76% | Trim |
| 22 | AVIR | Atea Pharmaceuticals INC | +0.2% | +79.41% | Add |
| 23 | STOK | Stoke Therapeutics INC | +0.1% | +0.72% | Add |
| 24 | ACOG | Alpha Cognition INC | +0.1% | +23.72% | Add |
| 25 | JBIO | Jade Biosciences INC | -0.1% | — | Unchanged |
| 26 | TECX | Tectonic Therapeutic INC | -0.1% | -42.72% | Trim |
| 27 | RIGL | Rigel Pharmaceuticals INC | -0.2% | — | Unchanged |
| 28 | FBIO | Fortress Biotech INC | -0.2% | -4.40% | Trim |
| 29 | DERM | Journey Medical CORP | -0.4% | -1.54% | Trim |
| 30 | PLX | Protalix Biotherapeutics INC | -0.5% | -86.28% | Trim |
| 31 | CGON | Cg Oncology INC | -1.4% | -76.88% | Trim |
| 32 | SNWV | Sanuwave Health INC | -1.6% | — | Unchanged |
| 33 | OCUL | Ocular Therapeutix INC | -1.9% | -62.38% | Trim |
| 34 | HROW | Harrow INC | -12.1% | -27.47% | Trim |
| 35 | ALKS | Alkermes plc | — | EXIT | Sold out |
| 36 | GOSS | Gossamer Bio INC | — | EXIT | Sold out |
| 37 | KPTI | Karyopharm Therapeutics INC | — | EXIT | Sold out |
| 38 | AH30 | Assertio Holdings INC | — | NEW | New buy |
| 39 | EDIT | Editas Medicine INC | — | NEW | New buy |
| 40 | BDSX | Biodesix INC | — | NEW | New buy |
| 41 | NTLA | Intellia Therapeutics INC | — | NEW | New buy |
| 42 | ZYME | Zymeworks INC | — | EXIT | Sold out |
| 43 | ✓ | Assertio Holdings INC | — | EXIT | Sold out |
| 44 | VTYXUSD | Ventyx Biosciences INC | — | EXIT | Sold out |
| 45 | ✓ | — | EXIT | Sold out | |
| 46 | LYEL | Lyell Immunopharma INC | — | NEW | New buy |
| 47 | NXTC | Nextcure INC | — | NEW | New buy |
| 48 | BBIO | Bridgebio Pharma INC | — | EXIT | Sold out |
| 49 | FDMT | 4d Molecular Therapeutics In | — | NEW | New buy |
| 50 | ✓ | Perspective Therapeutics INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-04-13 | Amendment | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-15 | Amendment | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-29 | Amendment | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-15 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-10 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-16 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-16 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-18 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-12 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-11-16 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-08-14 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-05-15 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-02-14 | 13F-HR | View on EDGAR |
| 2019-09-30 | 2019-11-14 | 13F-HR | View on EDGAR |
| 2019-06-30 | 2019-08-14 | 13F-HR | View on EDGAR |
| 2019-03-31 | 2019-05-15 | 13F-HR | View on EDGAR |
| 2018-12-31 | 2019-02-14 | 13F-HR | View on EDGAR |
| 2018-09-30 | 2018-11-14 | 13F-HR | View on EDGAR |
| 2018-06-30 | 2018-08-14 | 13F-HR | View on EDGAR |
| 2018-03-31 | 2018-05-14 | 13F-HR | View on EDGAR |
| 2017-12-31 | 2018-02-09 | 13F-HR | View on EDGAR |
| 2017-09-30 | 2017-11-14 | 13F-HR | View on EDGAR |
| 2017-06-30 | 2017-08-14 | 13F-HR | View on EDGAR |
| 2017-03-31 | 2017-05-15 | 13F-HR | View on EDGAR |
| 2016-12-31 | 2017-02-21 | 13F-HR | View on EDGAR |
| 2016-09-30 | 2016-11-14 | 13F-HR | View on EDGAR |
| 2016-06-30 | 2016-08-12 | 13F-HR | View on EDGAR |
| 2016-06-30 | 2016-08-12 | Amendment | View on EDGAR |
| 2016-03-31 | 2016-05-27 | Amendment | View on EDGAR |
| 2016-03-31 | 2016-05-16 | 13F-HR | View on EDGAR |
| 2015-12-31 | 2016-02-12 | 13F-HR | View on EDGAR |
| 2015-09-30 | 2015-11-13 | 13F-HR | View on EDGAR |
| 2015-06-30 | 2015-08-14 | 13F-HR | View on EDGAR |
| 2015-03-31 | 2015-05-15 | 13F-HR | View on EDGAR |
| 2014-12-31 | 2015-02-13 | 13F-HR | View on EDGAR |
| 2014-09-30 | 2014-11-14 | 13F-HR | View on EDGAR |
| 2014-06-30 | 2014-08-14 | 13F-HR | View on EDGAR |
| 2014-03-31 | 2014-05-15 | 13F-HR | View on EDGAR |
| 2013-12-31 | 2014-02-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001766157
Total reported value
$759.2M
271 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001845445
Total reported value
$758.8M
209 stks
2024-09-30
Stale — no recent filing
AUM within 0.1% of this institution
CIK 0001274196
Total reported value
$758.7M
39 stks
2025-09-30
Stale — no recent filing
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001037353
Total reported value
$4.3M
2 stks
2026-03-31
1 of the top 5 holdings overlap, including Liquidia CORP
CIK 0001058854
Total reported value
$162.9M
41 stks
2026-03-31
1 of the top 5 holdings overlap, including Eton Pharmaceuticals INC
CIK 0001176347
Total reported value
$620.1M
4 stks
2026-03-31
1 of the top 5 holdings overlap, including Rhythm Pharmaceuticals INC